factor XIII: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
factor XIII: clinical details
Prescribing considerations
- Individualise treatment using clinical response and factor XIII activity.
- Use caution after recent thrombosis because factor XIII stabilises fibrin.
- Consider sodium and glucose content where clinically relevant.
- Record product name and batch number for traceability.
- Consider hepatitis A and B vaccination for people receiving repeated plasma-derived factor XIII.
Contraindications and cautions
- Hypersensitivity to factor XIII or any excipient
Monitoring
- Assess bleeding control and wound healing.
- Measure factor XIII activity with an appropriate sensitive assay.
- Test for inhibitory antibodies if expected activity is not achieved or breakthrough bleeding occurs.
- Observe for immediate hypersensitivity during administration.
Clinical pharmacology
Plasma-derived factor XIII has transglutaminase activity that covalently cross-links fibrin, strengthening clots and supporting fibroblast penetration and wound healing. Intravenous administration makes it immediately bioavailable.
Formulation and product differences
- Powder supplied with water for injections and a transfer device
- Presentations differ in vial content and solvent volume but produce the same reconstituted concentration
- Contains human albumin, glucose and sodium
factor XIII interactions
Formal interaction studies have not been performed. Tell the haemophilia team about all medicines being used.
Other injectable medicines, diluents or solvents
Factor XIII must not be mixed with them and should be given through a separate line.
Non-steroidal anti-inflammatory medicines such as ibuprofen
These can add to the underlying bleeding risk; check suitable pain relief with the treating team.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.